As of Feb 12
| +0.12 / +1.29%|
The 6 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 20.00, with a high estimate of 28.00 and a low estimate of 14.00. The median estimate represents a +111.64% increase from the last price of 9.45.
The current consensus among 7 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.